Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment
Polymorphic variants in IL-17A gene were differentially associated with colorectal cancer (CRC) susceptibility but their link with response and toxicity to CRC treatment have not yet been evaluated. We investigated association between seven IL-17A variants with the response and toxicity to CRC treat...
Gespeichert in:
| Veröffentlicht in: | Cancer gene therapy 2020-05, Vol.27 (5), p.311-318 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 318 |
|---|---|
| container_issue | 5 |
| container_start_page | 311 |
| container_title | Cancer gene therapy |
| container_volume | 27 |
| creator | Bedoui, Sinda Dallel, Meriem Barbirou, Mouadh Stayoussef, Mouna Mokrani, Amina Mezlini, Amel Bouhaouala, Balkiss Almawi, Wassim Y. Yacoubi-Loueslati, Besma |
| description | Polymorphic variants in
IL-17A
gene were differentially associated with colorectal cancer (CRC) susceptibility but their link with response and toxicity to CRC treatment have not yet been evaluated. We investigated association between seven
IL-17A
variants with the response and toxicity to CRC treatment in 294 patients with CRC.
IL-17A
genotyping was done by real-time PCR. MAF of rs3748067 was significantly higher in CRC cases resistant to FOLFOX treatment (R+) than non resistant (R−). Significantly higher rs3804513 MAF was noted in R+ versus R− colon cancer (CC). Higher rs2275913 and rs10484879, and reduced rs3804513 MAF were seen in rectal cancer (RC) tolerant to FOLFOX (T+) compared to (T−) patients. Strong association of rs3819025, rs3804513, and rs7747909 was found with tolerance to RC treatment. rs3748067 was associated with FOLFOX tolerance in CC but not RC. Significant higher frequency of AGGCAGG and
GA
GCAGG haplotypes was seen among R + CC, thus assigning non-favorable nature to these haplotypes. Higher and lower frequencies of
GA
G
T
A
A
G and AGGC
T
G
A
haplotypes, respectively, were observed in T + RC, thereby assigning FOLFOX-tolerant and non-tolerant nature to these haplotypes. The obtained results suggest that IL-17A variants and haplotypes may be a target for future management of CRC treatment. |
| doi_str_mv | 10.1038/s41417-019-0102-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231857009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A624441335</galeid><sourcerecordid>A624441335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-e225f44243d085a3cd3e55321b72a600b45cce2638b5a2f2503e166f172874763</originalsourceid><addsrcrecordid>eNp1kt9qFDEUxgdR7Fp9AG8kIIg3U_N3MnO5FLcWFvZGwbuQzZzppGaSMckI-wC-d7NsrVaUEBKS3_dxTvJV1WuCLwhm7YfECSeyxqQrE9OaPKlWhMumFgLjp9UKd7SrSYfZWfUipVuMy6Vkz6szRghrO0xW1c9rnyE6WL5ZXxO5RnNwhynEebRpSmiO0FuTUR4BRUhz8AmQ9j3q4Qe4ME_gMwoDysFB1N5A2aHNbrvZfUVmhCkUYdTzAVmPTHAhgsnaIXNEI8oRdD5avKyeDdoleHW_nldfNh8_X36qt7ur68v1tjZc4lwDpWLgnHLW41ZoZnoGQjBK9pLqBuM9F8YAbVi7F5oOVGAGpGkGImkry7uw8-r9yXeO4fsCKavJJgPOaQ9hSYpSRlohMe4K-vYv9DYs0ZfqFOWYN1TIUscDdaMdKOuHkKM2R1O1bijnnDAmCnXxD6qMHiZrgofBlvNHgnd_CEbQLo8puCXb8gGPQXICTQwpRRjUHO2k40ERrI4ZUaeMqJIRdcyIIkXz5r6zZT9B_6D4FYoC0BOQypW_gfi79f-73gFCA8Q6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404625724</pqid></control><display><type>article</type><title>Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Bedoui, Sinda ; Dallel, Meriem ; Barbirou, Mouadh ; Stayoussef, Mouna ; Mokrani, Amina ; Mezlini, Amel ; Bouhaouala, Balkiss ; Almawi, Wassim Y. ; Yacoubi-Loueslati, Besma</creator><creatorcontrib>Bedoui, Sinda ; Dallel, Meriem ; Barbirou, Mouadh ; Stayoussef, Mouna ; Mokrani, Amina ; Mezlini, Amel ; Bouhaouala, Balkiss ; Almawi, Wassim Y. ; Yacoubi-Loueslati, Besma</creatorcontrib><description>Polymorphic variants in
IL-17A
gene were differentially associated with colorectal cancer (CRC) susceptibility but their link with response and toxicity to CRC treatment have not yet been evaluated. We investigated association between seven
IL-17A
variants with the response and toxicity to CRC treatment in 294 patients with CRC.
IL-17A
genotyping was done by real-time PCR. MAF of rs3748067 was significantly higher in CRC cases resistant to FOLFOX treatment (R+) than non resistant (R−). Significantly higher rs3804513 MAF was noted in R+ versus R− colon cancer (CC). Higher rs2275913 and rs10484879, and reduced rs3804513 MAF were seen in rectal cancer (RC) tolerant to FOLFOX (T+) compared to (T−) patients. Strong association of rs3819025, rs3804513, and rs7747909 was found with tolerance to RC treatment. rs3748067 was associated with FOLFOX tolerance in CC but not RC. Significant higher frequency of AGGCAGG and
GA
GCAGG haplotypes was seen among R + CC, thus assigning non-favorable nature to these haplotypes. Higher and lower frequencies of
GA
G
T
A
A
G and AGGC
T
G
A
haplotypes, respectively, were observed in T + RC, thereby assigning FOLFOX-tolerant and non-tolerant nature to these haplotypes. The obtained results suggest that IL-17A variants and haplotypes may be a target for future management of CRC treatment.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/s41417-019-0102-1</identifier><identifier>PMID: 31138901</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>45/22 ; 45/77 ; 631/208 ; 631/67 ; 692/699 ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer therapies ; Chemotherapy ; Colon cancer ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - genetics ; Colonic Neoplasms - pathology ; Colorectal cancer ; Colorectal carcinoma ; Cross-Sectional Studies ; Drug Resistance, Neoplasm - genetics ; Drug therapy ; Female ; Fluorouracil - pharmacology ; Fluorouracil - therapeutic use ; Gene Expression ; Gene Therapy ; Genetic aspects ; Genetic polymorphisms ; Genotyping ; Genotyping Techniques ; Haplotypes ; Health aspects ; Humans ; Interleukin-17 - genetics ; Leucovorin - pharmacology ; Leucovorin - therapeutic use ; Male ; Middle Aged ; Organoplatinum Compounds - pharmacology ; Organoplatinum Compounds - therapeutic use ; Polymorphism, Single Nucleotide ; Prognosis ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - genetics ; Rectal Neoplasms - pathology ; Rectum ; Retrospective Studies ; Toxicity ; Treatment Outcome</subject><ispartof>Cancer gene therapy, 2020-05, Vol.27 (5), p.311-318</ispartof><rights>Springer Nature America, Inc. 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>Springer Nature America, Inc. 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-e225f44243d085a3cd3e55321b72a600b45cce2638b5a2f2503e166f172874763</citedby><cites>FETCH-LOGICAL-c470t-e225f44243d085a3cd3e55321b72a600b45cce2638b5a2f2503e166f172874763</cites><orcidid>0000-0002-2553-9120</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41417-019-0102-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41417-019-0102-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31138901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bedoui, Sinda</creatorcontrib><creatorcontrib>Dallel, Meriem</creatorcontrib><creatorcontrib>Barbirou, Mouadh</creatorcontrib><creatorcontrib>Stayoussef, Mouna</creatorcontrib><creatorcontrib>Mokrani, Amina</creatorcontrib><creatorcontrib>Mezlini, Amel</creatorcontrib><creatorcontrib>Bouhaouala, Balkiss</creatorcontrib><creatorcontrib>Almawi, Wassim Y.</creatorcontrib><creatorcontrib>Yacoubi-Loueslati, Besma</creatorcontrib><title>Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>Polymorphic variants in
IL-17A
gene were differentially associated with colorectal cancer (CRC) susceptibility but their link with response and toxicity to CRC treatment have not yet been evaluated. We investigated association between seven
IL-17A
variants with the response and toxicity to CRC treatment in 294 patients with CRC.
IL-17A
genotyping was done by real-time PCR. MAF of rs3748067 was significantly higher in CRC cases resistant to FOLFOX treatment (R+) than non resistant (R−). Significantly higher rs3804513 MAF was noted in R+ versus R− colon cancer (CC). Higher rs2275913 and rs10484879, and reduced rs3804513 MAF were seen in rectal cancer (RC) tolerant to FOLFOX (T+) compared to (T−) patients. Strong association of rs3819025, rs3804513, and rs7747909 was found with tolerance to RC treatment. rs3748067 was associated with FOLFOX tolerance in CC but not RC. Significant higher frequency of AGGCAGG and
GA
GCAGG haplotypes was seen among R + CC, thus assigning non-favorable nature to these haplotypes. Higher and lower frequencies of
GA
G
T
A
A
G and AGGC
T
G
A
haplotypes, respectively, were observed in T + RC, thereby assigning FOLFOX-tolerant and non-tolerant nature to these haplotypes. The obtained results suggest that IL-17A variants and haplotypes may be a target for future management of CRC treatment.</description><subject>45/22</subject><subject>45/77</subject><subject>631/208</subject><subject>631/67</subject><subject>692/699</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Cross-Sectional Studies</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fluorouracil - pharmacology</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Genetic aspects</subject><subject>Genetic polymorphisms</subject><subject>Genotyping</subject><subject>Genotyping Techniques</subject><subject>Haplotypes</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Interleukin-17 - genetics</subject><subject>Leucovorin - pharmacology</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - pharmacology</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - genetics</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectum</subject><subject>Retrospective Studies</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kt9qFDEUxgdR7Fp9AG8kIIg3U_N3MnO5FLcWFvZGwbuQzZzppGaSMckI-wC-d7NsrVaUEBKS3_dxTvJV1WuCLwhm7YfECSeyxqQrE9OaPKlWhMumFgLjp9UKd7SrSYfZWfUipVuMy6Vkz6szRghrO0xW1c9rnyE6WL5ZXxO5RnNwhynEebRpSmiO0FuTUR4BRUhz8AmQ9j3q4Qe4ME_gMwoDysFB1N5A2aHNbrvZfUVmhCkUYdTzAVmPTHAhgsnaIXNEI8oRdD5avKyeDdoleHW_nldfNh8_X36qt7ur68v1tjZc4lwDpWLgnHLW41ZoZnoGQjBK9pLqBuM9F8YAbVi7F5oOVGAGpGkGImkry7uw8-r9yXeO4fsCKavJJgPOaQ9hSYpSRlohMe4K-vYv9DYs0ZfqFOWYN1TIUscDdaMdKOuHkKM2R1O1bijnnDAmCnXxD6qMHiZrgofBlvNHgnd_CEbQLo8puCXb8gGPQXICTQwpRRjUHO2k40ERrI4ZUaeMqJIRdcyIIkXz5r6zZT9B_6D4FYoC0BOQypW_gfi79f-73gFCA8Q6</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Bedoui, Sinda</creator><creator>Dallel, Meriem</creator><creator>Barbirou, Mouadh</creator><creator>Stayoussef, Mouna</creator><creator>Mokrani, Amina</creator><creator>Mezlini, Amel</creator><creator>Bouhaouala, Balkiss</creator><creator>Almawi, Wassim Y.</creator><creator>Yacoubi-Loueslati, Besma</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2553-9120</orcidid></search><sort><creationdate>20200501</creationdate><title>Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment</title><author>Bedoui, Sinda ; Dallel, Meriem ; Barbirou, Mouadh ; Stayoussef, Mouna ; Mokrani, Amina ; Mezlini, Amel ; Bouhaouala, Balkiss ; Almawi, Wassim Y. ; Yacoubi-Loueslati, Besma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-e225f44243d085a3cd3e55321b72a600b45cce2638b5a2f2503e166f172874763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>45/22</topic><topic>45/77</topic><topic>631/208</topic><topic>631/67</topic><topic>692/699</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Cross-Sectional Studies</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fluorouracil - pharmacology</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Genetic aspects</topic><topic>Genetic polymorphisms</topic><topic>Genotyping</topic><topic>Genotyping Techniques</topic><topic>Haplotypes</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Interleukin-17 - genetics</topic><topic>Leucovorin - pharmacology</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - pharmacology</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - genetics</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectum</topic><topic>Retrospective Studies</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bedoui, Sinda</creatorcontrib><creatorcontrib>Dallel, Meriem</creatorcontrib><creatorcontrib>Barbirou, Mouadh</creatorcontrib><creatorcontrib>Stayoussef, Mouna</creatorcontrib><creatorcontrib>Mokrani, Amina</creatorcontrib><creatorcontrib>Mezlini, Amel</creatorcontrib><creatorcontrib>Bouhaouala, Balkiss</creatorcontrib><creatorcontrib>Almawi, Wassim Y.</creatorcontrib><creatorcontrib>Yacoubi-Loueslati, Besma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bedoui, Sinda</au><au>Dallel, Meriem</au><au>Barbirou, Mouadh</au><au>Stayoussef, Mouna</au><au>Mokrani, Amina</au><au>Mezlini, Amel</au><au>Bouhaouala, Balkiss</au><au>Almawi, Wassim Y.</au><au>Yacoubi-Loueslati, Besma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>27</volume><issue>5</issue><spage>311</spage><epage>318</epage><pages>311-318</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>Polymorphic variants in
IL-17A
gene were differentially associated with colorectal cancer (CRC) susceptibility but their link with response and toxicity to CRC treatment have not yet been evaluated. We investigated association between seven
IL-17A
variants with the response and toxicity to CRC treatment in 294 patients with CRC.
IL-17A
genotyping was done by real-time PCR. MAF of rs3748067 was significantly higher in CRC cases resistant to FOLFOX treatment (R+) than non resistant (R−). Significantly higher rs3804513 MAF was noted in R+ versus R− colon cancer (CC). Higher rs2275913 and rs10484879, and reduced rs3804513 MAF were seen in rectal cancer (RC) tolerant to FOLFOX (T+) compared to (T−) patients. Strong association of rs3819025, rs3804513, and rs7747909 was found with tolerance to RC treatment. rs3748067 was associated with FOLFOX tolerance in CC but not RC. Significant higher frequency of AGGCAGG and
GA
GCAGG haplotypes was seen among R + CC, thus assigning non-favorable nature to these haplotypes. Higher and lower frequencies of
GA
G
T
A
A
G and AGGC
T
G
A
haplotypes, respectively, were observed in T + RC, thereby assigning FOLFOX-tolerant and non-tolerant nature to these haplotypes. The obtained results suggest that IL-17A variants and haplotypes may be a target for future management of CRC treatment.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>31138901</pmid><doi>10.1038/s41417-019-0102-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2553-9120</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-1903 |
| ispartof | Cancer gene therapy, 2020-05, Vol.27 (5), p.311-318 |
| issn | 0929-1903 1476-5500 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2231857009 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | 45/22 45/77 631/208 631/67 692/699 Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Cancer therapies Chemotherapy Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - genetics Colonic Neoplasms - pathology Colorectal cancer Colorectal carcinoma Cross-Sectional Studies Drug Resistance, Neoplasm - genetics Drug therapy Female Fluorouracil - pharmacology Fluorouracil - therapeutic use Gene Expression Gene Therapy Genetic aspects Genetic polymorphisms Genotyping Genotyping Techniques Haplotypes Health aspects Humans Interleukin-17 - genetics Leucovorin - pharmacology Leucovorin - therapeutic use Male Middle Aged Organoplatinum Compounds - pharmacology Organoplatinum Compounds - therapeutic use Polymorphism, Single Nucleotide Prognosis Rectal Neoplasms - drug therapy Rectal Neoplasms - genetics Rectal Neoplasms - pathology Rectum Retrospective Studies Toxicity Treatment Outcome |
| title | Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-17A%20polymorphisms%20predict%20the%20response%20and%20development%20of%20tolerance%20to%20FOLFOX%20chemotherapy%20in%20colorectal%20cancer%20treatment&rft.jtitle=Cancer%20gene%20therapy&rft.au=Bedoui,%20Sinda&rft.date=2020-05-01&rft.volume=27&rft.issue=5&rft.spage=311&rft.epage=318&rft.pages=311-318&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/s41417-019-0102-1&rft_dat=%3Cgale_proqu%3EA624441335%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2404625724&rft_id=info:pmid/31138901&rft_galeid=A624441335&rfr_iscdi=true |